Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer

Launched by NATIONAL CANCER CENTER, KOREA · Dec 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how different ways of making treatment decisions can impact patients with low-risk thyroid cancer, specifically a type called papillary thyroid carcinoma. The trial compares two groups: one that uses "Shared Decision-Making" (SDM), where patients and doctors work together to choose the best treatment, and another that follows standard care practices. The goal is to see if involving patients more in their treatment choices leads to better outcomes.

To be eligible for the trial, participants should be adults aged 18 or older who have a thyroid nodule that is 1.5 cm or smaller and shows signs of being suspicious or cancerous based on lab tests. They should not have any serious complications or advanced cancer that has spread to other areas. If you join the study, you can expect to participate in discussions about your treatment options and help make decisions about your care alongside healthcare providers. The trial is currently not recruiting participants, so it's important to stay updated if you're interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18 years or older with a thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.
• • Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype).
• Exclusion Criteria:
• • Patients who cannot undergo regular follow-up or are expected to have difficulties with follow-up.
• • Patients with indeterminate or benign findings on thyroid biopsy.